Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR   US00484M1062

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/27/2015 03/02/2015 03/03/2015 03/04/2015 03/05/2015 Date
33.84(c) 35.01(c) 35.2(c) 35.74(c) 36.08 Last
1 445 053 1 171 011 567 871 473 051 142 258 Volume
-4.84% +3.46% +0.54% +1.53% +0.95% Change
More quotes
Company
Acorda Therapeutics, Inc. engages in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system.The company's two main products are Ampyra and Zanaflex... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 454 M
EBIT 2015 1,95 M
Net income 2015 -22,4 M
Finance 2015 25,5 M
Yield 2015 -
Sales 2016 512 M
EBIT 2016 40,5 M
Net income 2016 -12,4 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 3,29x
Capi. / Sales 2016 2,97x
Capitalization 1 522 M
More Financials
Latest news on ACORDA THERAPEUTICS INC
03/04 ACORDA THERAPEUTICS : Mayo Foundation for Medical Education & Research, Acorda T..
03/04 ACORDA THERAPEUTICS : to Present at the Barclays Global Healthcare Conference
02/23 ACORDA THERAPEUTICS : to Present at the Cowen 35th Annual Health Care Conference
02/17 ACORDA THERAPEUTICS : to Present at the 2015 RBC Capital Markets’ Healthca..
02/12 ACORDA THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
02/12 ACORDA THERAPEUTICS : beats Street 4Q forecasts
02/12 ACORDA THERAPEUTICS : Reports Fourth Quarter and Full Year 2014 Financial Result..
02/11 ACORDA THERAPEUTICS : Announces Safety and Tolerability Data from First Clinical..
More news
Sector news Bio Therapeutic Drugs
11:07aDJAbbVie to Buy Pharmacyclics in $21 Billion Deal -- 3rd Update
10:32a AbbVie says Pharmacyclics drug, new form of Humira to lift company
10:30aDJMARKET SNAPSHOT : U.S. Stocks Rise As Draghi Outlines QE Game Plan
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF